GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
Orchestrating & Driving GMP Batch Success, Capacity, and Global Scale - BRG
I’m a paragraph. Drag me to add paragraph to your block, write your own text and edit me.
OUTCOMES & RESULTS
☑ OPS/QUALITY: BIOMANUFACTURING PERFORMANCE 🏆 ☑ OPS: NEW LEVEL OF BIOMANUFACTURING CONFIDENCE ☑ GEOPOLITICS: GEO-DIVERSIFIED BIOMANUFACTURING ☑ STRATEGY: MEET ALL PROGRAM MILESTONES ☑ CAPACITY: MORE DOSES PER CAPEX DOLLAR ☑ CAPACITY: PROCESS INTENSIFICATION ☑ CAPACITY: CONTINUOUS MANUFACTURING ☑ CAPACITY: CAPACITY EXPANSION - ACTIVE ☑ BIZ DEV: INCREASED CUSTOMER CONFIDENCE ☑ PEOPLE: ATTRACT & RETAIN TOP TALENT ☑ FACILITY/CAPACITY: ASSET UTILIZATION HIGH ☑ EXTERNAL SUPPLIERS: EPC SELECTION - ACTIVE ☑ EXTERNAL SUPPLIERS: SITE SELECTION ACTIVE
Let's partner-up to identify areas where our collective action can accelerate your Biomanufacturing transformation. We'll focus and drive GMP Batch Success, Capacity, and Global Scale.
YES, LET's GET THIS DONE!
PERSISTENT CHALLENGES?
Biopharma companies encounter a variety of frustratingly persistent GMP challenges. This can be intensely uncomfortable for you, your teams, communities, and patients. As global consultants, we see a lot. We are fully aware that these issues are frustratingly persistent and painful. The list below may look familiar. Let's fix this. FACILITY / PROCESS / CAPACITY / OPS ♦ Underutilized Manufacturing Capacity (<50%) ♦ Persistent Contamination Issues ♦ Older technology / Equipment ♦ Need to make more doses without more CAPEX PEOPLE ♦ Layoffs (again?) ♦ Cannot predictably attract/hire/retain talent ♦ Manufacturing Reshoring is draining my bullpen QUALITY ♦ Elevated QMS/Regulatory Scrutiny ♦ Persistent Contamination Issues / Open CAPA EXTERNAL MANUFACTURING / SUPPLIERS ♦ Need a CDMO (DS/DP) in the USA ♦ Need an EPC Vendor (New facility) ♦ Need a new GMP Site (New facility)

STUCK? Take our risk-free, fast (4min) GMP ASSESSMENT to evaluate your site's challenges.

WHAT HAPPENS WHEN WE CONNECT?
Partnering closely with CDMO and INNOVATOR biotech companies small and large, the BRG team delivers solutions that target your core operational challenges and advance your most important business goals. We are exceptionally strong advocates for your: PEOPLE, PLANT, PROCESS, PRODUCT, PATIENTS Leveraging our BRIDGEONE SERVICES framework, you'll observe a straightforward, transparent GMP Services Ecosystem. From Concept through Commercial Launch, we'll guide you with clear, practical steps to help your teams and stakeholders achieve new levels of performance and confidence. Working alongside BRG, we'll achieve outcomes and results that drive GMP Batch Success, Capacity, and Global Scale. This drives us to: ♦ Work Together: Your Team, Your Site(s), Your Victory ♦ Pencils to Paper, On plant, Hands-on ♦ Let's create a plan of practical steps to: - Elevate your GMP Position - Achieve + Sustain New Levels of Performance
GMP IS IN OUR DNA
"Resolving a major company pain-point significantly lowers internal tension, fostering a more collaborative and productive work environment. You will improve and begin to Catalyze Great Manufacturing Performance." - Susan Valdes
GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
BRG Updates: Autumn 2025
LET'S CRUSH YOUR 2026 GMP GOALS!
SANTA SENT US A VIDEO! Ho-Ho-Ho!
GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
The next move is yours...
"In biotechnology manufacturing (GMP), we live in remarkably changing times. Ideas and approaches that worked five years ago don't work today. Given that global biotechnology is under extreme pressure to innovate and put points on the board, 2026-2036 will be both challenging and inspiring. Global competition is frustratingly intense. Being good isn’t good enough. Companies (people, process, factory, value-chain) need to sustainably improve, differentiate, and reinvent. RULE 1: START BUYING RESULTS & OUTCOMES, NOT GENERALIST OVERHEAD. RULE 2: DOING NOTHING IS NOT AN OPTION. a. BE MINDFUL OF THE CONSEQUENCES OF INACTION. Some biotech companies will see the next decade as a tsunami-of-change that sweeps their complacent company out to sea. Others will be more aware, prepare, hedge, learn to surf, and reap the benefits. BRG's primary focus is to transform your GMP position and achieve new levels of performance and confidence. Only then will your team become enviable, essential, and unassailable." - Bob V.
"Let's partner to identify areas where our collective action can accelerate your manufacturing transformation." - Bob Valdes
Robert Valdes (Bob) GMP BioManufacturing Orchestrator bobv@biotech-1.com 202.738.338SIX Washington, D.C. Metro Boston Metro
I’m a paragraph. Drag me to add paragraph to your block, write your own text and edit me.
Process Intensification (PI) and Continuous Manufacturing (CM): Let's Reshape the Economics of Your Tox, Clinical, and Commercial Biologics Supply
Biotech Manufacturing is shifting toward lights-out, end-to-end (e2e), continuous, and Intensified bioprocessing where automation and advanced analytics are already delivering meaningful cost and agility gains over conventional fed-batch plants. Over the next decade, this shift will drive step-change efficiency in nearly every biomanufacturing modality, and this is exactly where, when, why, and how BIOTECH RESOURCES GROUP supports biomanufacturing leadership teams. Working shoulder-to-shoulder, we'll turn next-gen platforms into tangible COG's reductions, smaller/cost-effective footprints, and a more flexible, predictable, resilient global supply chain. Let's Connect! - M.J.
Process Intensification/CM Experience/Expertise?
Would you like your Company featured in this E-book?
GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
GMP IS IN OUR DNA ® GMP IS IN OUR pDNA ® GMP IS IN OUR mRNA ® SUCCESS IS IN YOUR DNA © BIOTECHNOLOGY cGMP CONSULTING
© 2026 Biotech Resources Group, LLC
GMP IS IN OUR DNA ROBERT VALDES MSC, MBA
"Driving GMP Batch Success, Capacity, and Global Scale"- BRG